EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer

Despite the success of treating EGFR mutant lung cancer patients with EGFR tyrosine kinase inhibitors (TKIs), all patients eventually acquire resistance to these therapies. Although various resistance mechanisms have been described, there are currently no FDA-approved therapies that target alternati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Amato, Katherine R., Wang, Shan, Tan, Li, Hastings, Andrew K., Song, Wenqiang, Lovly, Christine M., Meador, Catherine B., Ye, Fei, Lu, Pengcheng, Balko, Justin M., Colvin, Daniel C., Cates, Justin M., Pao, William, Gray, Nathanael S., Chen, Jin
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4715957/
https://ncbi.nlm.nih.gov/pubmed/26744526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-0717
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados